Trinity Biotech (TRIB) Getting Somewhat Positive News Coverage, Report Shows

Media headlines about Trinity Biotech (NASDAQ:TRIB) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trinity Biotech earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.731046319352 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Several analysts have commented on TRIB shares. Zacks Investment Research raised shares of Trinity Biotech from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. ValuEngine lowered shares of Trinity Biotech from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd.

Shares of TRIB stock opened at $5.08 on Monday. The stock has a market capitalization of $122.13, a price-to-earnings ratio of 19.54 and a beta of 1.31. The company has a debt-to-equity ratio of 1.45, a quick ratio of 3.76 and a current ratio of 5.30. Trinity Biotech has a 52 week low of $4.22 and a 52 week high of $6.54.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings data on Wednesday, March 7th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.07 by $0.01. The business had revenue of $24.55 million for the quarter, compared to analyst estimates of $23.53 million. Trinity Biotech had a negative net margin of 40.62% and a positive return on equity of 2.37%. research analysts predict that Trinity Biotech will post 0.07 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3343423/trinity-biotech-trib-getting-somewhat-positive-news-coverage-report-shows.html.

Trinity Biotech Company Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Insider Buying and Selling by Quarter for Trinity Biotech (NASDAQ:TRIB)

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Geron  Stock Rating Lowered by BidaskClub
Geron Stock Rating Lowered by BidaskClub
BidaskClub Upgrades eBay  to “Hold”
BidaskClub Upgrades eBay to “Hold”
BidaskClub Upgrades 8Point3 Energy Partners  to “Hold”
BidaskClub Upgrades 8Point3 Energy Partners to “Hold”
AppFolio  Rating Increased to Strong-Buy at BidaskClub
AppFolio Rating Increased to Strong-Buy at BidaskClub
Acorda Therapeutics  Rating Lowered to Hold at BidaskClub
Acorda Therapeutics Rating Lowered to Hold at BidaskClub
Q2 2018 Earnings Estimate for East West Bancorp  Issued By Wedbush
Q2 2018 Earnings Estimate for East West Bancorp Issued By Wedbush


Leave a Reply

© 2006-2018 Ticker Report. Google+.